1. Home
  2. SPRO vs TSE Comparison

SPRO vs TSE Comparison

Compare SPRO & TSE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SPRO
  • TSE
  • Stock Information
  • Founded
  • SPRO 2013
  • TSE 2010
  • Country
  • SPRO United States
  • TSE United States
  • Employees
  • SPRO N/A
  • TSE N/A
  • Industry
  • SPRO Biotechnology: Pharmaceutical Preparations
  • TSE Major Chemicals
  • Sector
  • SPRO Health Care
  • TSE Industrials
  • Exchange
  • SPRO Nasdaq
  • TSE Nasdaq
  • Market Cap
  • SPRO 110.9M
  • TSE 91.0M
  • IPO Year
  • SPRO 2017
  • TSE 2014
  • Fundamental
  • Price
  • SPRO $2.13
  • TSE $2.05
  • Analyst Decision
  • SPRO Buy
  • TSE
  • Analyst Count
  • SPRO 4
  • TSE 0
  • Target Price
  • SPRO $5.00
  • TSE N/A
  • AVG Volume (30 Days)
  • SPRO 308.6K
  • TSE 251.6K
  • Earning Date
  • SPRO 11-13-2025
  • TSE 11-05-2025
  • Dividend Yield
  • SPRO N/A
  • TSE 1.96%
  • EPS Growth
  • SPRO N/A
  • TSE N/A
  • EPS
  • SPRO N/A
  • TSE N/A
  • Revenue
  • SPRO $48,576,000.00
  • TSE $3,258,300,000.00
  • Revenue This Year
  • SPRO N/A
  • TSE N/A
  • Revenue Next Year
  • SPRO N/A
  • TSE $5.09
  • P/E Ratio
  • SPRO N/A
  • TSE N/A
  • Revenue Growth
  • SPRO N/A
  • TSE N/A
  • 52 Week Low
  • SPRO $0.51
  • TSE $1.90
  • 52 Week High
  • SPRO $3.22
  • TSE $6.90
  • Technical
  • Relative Strength Index (RSI)
  • SPRO 60.07
  • TSE 33.02
  • Support Level
  • SPRO $1.84
  • TSE $2.21
  • Resistance Level
  • SPRO $2.05
  • TSE $2.41
  • Average True Range (ATR)
  • SPRO 0.08
  • TSE 0.16
  • MACD
  • SPRO 0.03
  • TSE -0.04
  • Stochastic Oscillator
  • SPRO 85.71
  • TSE 5.18

About SPRO Spero Therapeutics Inc.

Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.

About TSE Trinseo PLC

Trinseo PLC is a materials company and manufacturer of latex and plastics products. The company's operating segments include Latex Binders, Americas Styrenics, Engineered Materials, and Polymer Solutions. Maximum revenue is generated from its Polymer Solutions segment, which consists of various polymers, the majority of which are for automotive, building, and construction applications. The product offerings of this segment include ABS, styrene-acrylonitrile, polystyrene, and polycarbonate products, which are marketed through brands like Magnum and Styron. Geographically, the company generates maximum revenue from Europe, followed by the United States, Asia-Pacific, and the Rest of the world.

Share on Social Networks: